血清白蛋白在经典型霍奇金淋巴瘤的临床意义

Clinical Significance of Serum Albumin in Classical Hodgkin's Lymphoma

目的:探讨血清白蛋白(ALB)水平在经典型霍奇金淋巴瘤(CHL)患者预后中的意义。方法:收集2001年5月至2008年12月在中山大学肿瘤防治中心经病理确诊初治的96例经典型霍奇金淋巴瘤患者的临床资料进行回顾性分析。根据ALB水平比较患者的总生存率(OS)和无失败生存率(FFS)。结果:治疗前96例经典型霍奇金淋巴瘤患者中有17例ALB<35 g/L及79例ALB≥35 g/L。比较两组患者的基线临床特征,结果显示在年龄、性别、Ann Arbor分期、巨大肿块、结外侵犯、淋巴结区域、LDH水平比较均无统计学差异(P>0.05)。ALB<35 g/L和ALB≥35 g/L患者的5年FFS分别为60.1%和91.6%(P=0.022),但OS并无统计学意义(P=0.131)。多因素分析结果示仅ALB<35 g/L是FFS的独立预后不良因素(P=0.030),而OS的独立预后因素为年龄≥60岁(P=0.020)。结论:本研究结果显示治疗前ALB水平对判断CHL患者的预后有一定临床意义,其可能成为一项新的预后指标用于早晚期CHL患者。

Objective： To investigate the clinical significance of serum albumin （ALB） level in the prognosis of classical Hodgkin＇s Lymphoma （ CHL ） patients. Methods： Clinical data from 96 pathologically confirmed, previously untreated CHL patients in Sun Yat-Sen University Cancer Center between May 2001 and December 2008 were analyzed. Overall survival （ OS ） and failure free survival （FFS） were compared in terms of ALB levels. Results： Before treatment, 17 patients had ALB 〈 35 g/L and 79 patients had ALB ≥ 35 g/L among the 96 CHL patients. Comparison of the baseline clinical characteristics of the two groups revealed no significant differences in age, gender, Ann Arbor staging, bulky mass, extranodal involvement, lymph nodal sites, and lactate dehydrogenase （ LDH ） level （ P 〉 0.05 ）. The 5-year FFS rates for patients with ALB 〈 35 g/L and ALB ≥ 35 g/L were 60.1% and 91.6%, respectively （ P = 0.028 ）, but OS had no statistical significance （ P=0.131 ）. Multivariate analysis showed that the only independent adverse prognostic factor of FFS was ALB 〈 35 g/L （ P= 0.030 ）, and age ≥60was an independent prognostic predictor ofOS （ P = 0.020 ）. Conclusion： The ALB level at diagnosis is of clinical significance in the prognosis of CHL. For both early and advanced CHL patients, ALB might be a novel prognostic indicator.